20230424-太平洋-金域医学-603882.SH-第一季度常规诊断服务加速恢复_经营性现金流增长良好_5页_1mb

Summary of Jin Yu Medical 2023 Q1 and 2022 Annual Report

Financial Performance

Goldfield Medical Co., Ltd. (603882) published its 2022 annual report and 2023 first-quarter report on April 24, 2023. In 2022, revenue reached 15,476 billion yuan, up 2,958%; net profit attributable to shareholders was 2,753 billion yuan, up 2402%; and operating cash flow net was 1,948 billion yuan, down 671%. For the first quarter of 2023, revenue decreased by 50.19% to 211.8 billion yuan, with net profit down 82.40% to 15 billion yuan, but operating cash flow grew sharply by 1,4347% to 22 billion yuan, driven by recovery in routine diagnostic services.

Business Development

The company focused on medical testing, with significant growth in its medical laboratory services, achieving a 285.4% revenue increase in 2022. Profitability improved as 40 out of 48 medical labs became profitable, and losses narrowed. Customer structure was optimized, with a 38.40% share in three key disease lines and a shift to higher-end platforms. Medical resource accessibility was enhanced through partnerships and new projects.

Financial Efficiency

Costs were effectively managed: gross margin decreased by 41.6 percentage points to 43.13%; operating expenses fell significantly, with net profit margin declining to 18.37%. In Q1 2023, expenses saw mixed changes, but a large credit impairment loss impacted net profit margin.

Future Outlook

Maintaining a "Buy" recommendation with a target price of 100 yuan. Forecasts project revenue of 10,612 billion yuan for 2023 (down 31.43%), with net profit growth resuming in 2024 and 2025. The company emphasizes routine diagnostic recovery and potential growth in specific segments, despite risks like credit risk and regulatory changes.